AKTX Akari Therapeutics Plc
Price Chart
Executive Summary
Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate the development of its novel PH1 payload for its lead antibody-drug conjugate (ADC) candidate, AKTX-101, targeting metastatic urothelial cancer. The collaboration leverages WuXi XDC's expertise in ADC development and manufacturing to advance Akari’s preclinical program toward a Phase 1 trial expected in late 2026 or early 2027.
Actionable Insight
The partnership de-risks early-stage development by leveraging WuXi XDC’s ADC expertise, but without disclosed funding or milestone payments, near-term financial impact is limited. Traders should monitor for future IND submission and Phase 1 initiation as key catalysts.
Key Facts
- Akari Therapeutics partnered with WuXi XDC to develop its PH1 payload for AKTX-101, an ADC targeting metastatic urothelial cancer.
- PH1 is a novel spliceosome modulator payload that disrupts RNA splicing in cancer cells, differentiating it from traditional ADCs.
- Preclinical studies show AKTX-101 has superior anti-tumor regression and complete remissions compared to other ADCs.
- Phase 1 clinical trial initiation is expected in late 2026 or early 2027, subject to regulatory clearance.
- No financial terms of the partnership were disclosed.
Financial Impact
undisclosed amount
Risk Factors
- Clinical development risk: AKTX-101 has not yet entered human trials.
- No financial terms disclosed — potential lack of immediate capital infusion.
- Dependence on successful regulatory clearance and trial initiation timelines.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268442 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
15d ago
|
Press Release
| $22.05 $14.99 | ▼ −32.04% | ▼ −31.99% | $13.40 (−39.23%) |
|
May 22, 2026
21d ago
|
8-K
| $17.81 $13.43 | ▲ +24.59% | ▲ +25.68% | $13.40 (+24.76%) |
|
May 21, 2026
23d ago
|
Press Release
| $5.14 $22.05 | ▼ −328.99% | ▼ −327.39% | $13.40 (−160.70%) |
|
May 12, 2026
4w ago
|
Press Release
| $3.06 $3.50 | ▲ +14.38% | ▲ +14.30% | $13.40 (+337.91%) |
|
Apr 16, 2026
8w ago
|
EFFECT
| $5.12 $6.00 | ▼ −17.19% | ▼ −16.20% | $13.40 (−161.72%) |
|
Apr 9, 2026
9w ago
|
Press Release
| $3.92 $5.12 | ▲ +30.61% | ▲ +27.43% | $13.40 (+241.84%) |
|
Apr 6, 2026
9w ago
|
Press Release
| $3.54 $4.25 | ▲ +20.00% | ▲ +15.87% | $13.40 (+278.53%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $6.52 $5.48 | ▼ −15.95% | ▼ −15.24% | $13.40 (+105.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access